West Virginia Medicaid Drug Utilization Review Board Minutes

September 20, 2017

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD (via phone)
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Ernest Miller, DO
Michael Lonsinger, PharmD
Scott Brown, RPh (via phone)
Kate Forman, PharmD
Michael Ballow, PharmD (via phone)
John Vanin, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant
Gail Goodnight, RPh, Rebate Coordinator

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Goold Health Systems
Taylor DeRuiter, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:08 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM May 31, 2017 DUR BOARD MEETING

A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

A. None

IV. NEW BUSINESS

A. Speakers

1.	Carolyn McMicken	Neurocrine Biosciences	Ingrezza
2.	Danielle Ashley	Dermatology Associates	Eucrisa
3.	Robin Klapproth	Patient Advocate	Chantix
4.	Ahmad Nessar	Amgen	Repatha
5.	Greg Kitchens	Artia Solutions	Emflaza

B. Updates from the August 23, 2017 Pharmacy & Therapeutics Committee Meeting

1. Dr. Labus and the Board reviewed the updates from the August 26, 2017, P&T meeting (Attachment A). No criteria changes were requested beyond those presented in section III-C of this document.

C. PDL Prior Authorization Criteria (Attachment B)

1. **Austedo** – A motion to approve the criteria as presented was made, seconded, and passed.
2. **Chantix** – The Board agreed to amend the criteria as presented to allow a review for maintenance therapy of Chantix. A motion to approve the criteria as amended was made, seconded, and passed.
3. **Emflaza** – The Board agreed to amend the criteria as presented to require the prescriber be a neurologist. A request was made for clarification of how treatment failure with prednisone therapy be determined and what metrics to use. A motion to hold for review at the next DUR Board meeting was made, seconded and passed.
4. **Eucrisa** – The Board agreed to amend the criteria as presented to require a trial of a medium to high potency topical corticosteroid or a trial of Elidel. A motion to approve the criteria as amended was made, seconded and passed.
5. **GLP-1 agonists (DUR edit)** – The Board was notified about the removal of an edit that prevented GLP-1 agonists to be used with insulin therapy.
6. **Ingrezza** – A motion to approve the criteria as presented was made, seconded, and passed.
7. **Korlym** – The Board agreed to amend the criteria as presented to require that a patient must have inadequate results or a contraindication to treatment with a combination of metformin, insulin, and a GLP-1 agonist. A motion to approve the criteria as amended was made, seconded and passed.
8. **Onfi** – The Board was notified about a change to the PDL to require only a diagnosis of Lennox-Gastaut syndrome for approval of Onfi.
9. **Ophthalmics, Anti-inflammatories –** The Board was notified about a change to the PDL to only require 5-day trials of 2 preferred agents in the class before non-preferred agents can be used.

10. **PCSK9 Inhibitors** – The Board agreed to amend the criteria to remove requirements of liver function tests. The Board requested that all lipid lowering agents be reviewed for consideration as additional prior therapy options and/or requirements for approval. A motion to hold for review at the next DUR Board meeting was made, seconded and passed.
11. **Remicade** - The Board agreed to amend the criteria as presented to require that the request be made by or in consultation with an appropriate specialist. A motion to approve the criteria as amended was made, seconded and passed.
12. **Riluzole** – A motion to approve the criteria as presented was made, seconded, and passed.
13. **Spinraza** – A motion to approve the criteria as presented was made, seconded, and passed.
14. **Xenazine** – The Board agreed to amend the criteria as presented to require that the request must come from a neurologist. A motion to approve the criteria as amended was made, seconded, and passed.

V. REPORTS

A. Molina Quarterly Report – Second Quarter 2017 – Eric Sears presented an overview of the Molina 2017 Second Quarter Report (Attachment C). The presentation included a review of the DUR Quarterly Overall Summary Report.

B. Rational Drug Therapy Program – Steve Small presented a review of the prior authorization program for the Second Quarter 2017.

C. Health Information Designs – Matthew Waldrop presented an overview of the Second Quarter 2017 retrospective drug utilization activity (Attachment D). The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

A. None

VII. NEXT MEETING AND ADJOURNMENT

A. A motion to adjourn the meeting was made, seconded, and passed.

B. The meeting concluded at 6:40 p.m. EDT.

C. The next meeting will be Wednesday, November 15, 2017 from 4:00 p.m.–6:00 p.m. and located at WVDHR.

Submitted by:
Taylor DeRuiter, PharmD, Health Information Designs